Degradation of lipid based drug delivery formulations during nebulisation

Authors: David M. Klein, Frank M. Verhoeven, Daniel Bonn, Sylvestre Bonnet, Cees J.M. van Rijn

Journal: Chemical Physics, Volume 547, 2021

Abstract: Encapsulating pharmaceuticals in protective lipid based nanoparticles, and nebulising them towards the target area in the body offers a range of clinical advantages. However, the process of nebulization might possibly damage sensitive nanoparticle structures, such as liposomes, resulting in loss of active pharmaceutical ingredients. We compare this loss for two types of lung inhalation devices: high-frequency piezo-actuated vibrating mesh nebulisers and non-actuated continuous jet nebulisers. We find that vibrating mesh nebulisers cause model liposomes to release more than ten times as much encapsulated material as the continuous jet nebulisers because the energies involved in nebulisation are much larger. This result highlights the importance of applying a mild nebulisation technology when administering shear-sensitive drug formulations such as lipid nanoparticle based drugs to the lungs.

The content describes the in vitro performance of the Pulmospray® device with Respi Lever Drive™ and modelling of the distribution of the aerosol within the airways. Mimetikos Preludium® software from Emmace Consulting has been used for the modelling.

The data presented shows that the Pulmospray® disposable soft mist nebuliser has a high lung dose of 53 to 61% of the emitted dose. Pulmospray® provides a viable solution for fast and convenient drug delivery as it is often required for hospital use and/or the treatment of infectious diseases.